

Technology Advisory Committee A Interests Register

Publication Date: 26/05/2021

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

| Name | Role with NICE | Type of interest | Description of interest | Interest arose | Interest declared | Interest ceased | Comments |
|------------------------|-----------------|----------------------------|--|----------------|-------------------|-----------------|---|
| Professor Peter Schmid | Clinical Expert | Direct financial interests | Received consultancy fees and honorarium from: AstraZeneca, Bayer, Boehringer Ingelheim, Merck, Novartis, Pfizer, Puma and Roche | NA | 07/08/2020 | NA | It was agreed that this declaration would not prevent Professor Schmid from providing expert advice to the committee. |
| Professor Peter Schmid | Clinical Expert | Direct financial interests | Specific to Daiichi Sankyo: Professor Schmid is the National Advisory Board Chair since 27 March 2020, attended the European Advisory Board meeting on 4 February 2020 and was a principal investigator Destiny trial programme. | NA | 07/08/2020 | NA | It was agreed that these declarations would not prevent Professor Schmid from providing expert advice to the committee. |
| Professor Peter Schmid | Clinical Expert | Indirect interests | His institution received funding from: Astellas, AstraZeneca, Genentech, Novartis, Oncogenex, Roche. | NA | 07/08/2020 | NA | It was agreed that this declaration would not prevent Professor Schmid from providing expert advice to the committee. |

| | | | | | | | |
|------------------------|-----------------|--------------------------------|---|----|------------|----|---|
| Professor Peter Schmid | Clinical Expert | Direct financial interests | Received honorarium from Daichii | NA | 18/02/2021 | NA | It was agreed that this declaration would not prevent Professor Schmid from providing expert advice to the committee. |
| Holly Heath | Patient Expert | Indirect interests | Holly's employer, Breast Cancer Now, received funding from various pharma companies, including a grant to the helpline from Daiichi Sankyo in autumn 2020, for £22,559. | NA | 18/02/2021 | NA | It was agreed that this declaration would not prevent Holly from providing expert advice to the committee. |
| Claire Myerson | Patient Expert | Direct financial interests | Received honoraria in the past year for patient advocacy advice and input to breast cancer patient information projects at Novartis Pharma Corporation/Novartis UK. | NA | 11/01/2021 | NA | It was agreed that this declaration would not prevent Claire from providing expert advice to the committee. |
| Claire Myerson | Patient Expert | Direct non-financial interests | In the past year, Claire was a volunteer member of CRUK Patient Insights Panel, giving patient advocacy advice/input to projects at CRUK. She also contributed her patient experience to Breast Cancer Now fundraising and awareness campaigns. | NA | 11/01/2021 | NA | It was agreed that these declarations would not prevent Claire from providing expert advice to the committee. |

